ViCapsys Life Sciences

Vicapsys is a development-stage biotechnology company focused on localized immune modulation technologies designed to reduce transplant rejection, fibrosis, and foreign body responses without systemic immunosuppression. Its core platform is based on formulations of the cytokine CXCL12, licensed from Massachusetts General Hospital, and is being applied across cellular transplantation and non-cellular surgical indications. The company’s lead product line, VICAPSYN, is being developed initially for pancreatic islet cell transplantation in type 1 diabetes, with additional applications in diabetic foot ulcers, abdominal adhesions, and scar-related fibrosis. Vicapsys appears to remain a small public OTC-listed company with an early-stage pipeline and limited disclosed operating scale.